TABLE 2.
Univariate and multivariate survival analysis for disease‐free survival (DFS) in HCC patients.
Variables | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | p‐value | HR (95% CI) | p‐value | |
Gender | 0.88 (0.70–1.10) | 0.256 | ||
Age (year) | 0.99 (0.98–1.00) | 0.005 | ||
HBV (yes) | 1.16 (0.92–1.45) | 0.202 | ||
Hepatocirrhosis (yes) | 1.23 (1.02–1.47) | 0.028 | 1.25 (1.03, 1.52) | 0.023 |
Child‐Pugh grade (2) | 1.44 (1.02–2.05) | 0.041 | ||
AFP (ng/mL) | 1.00 (1.00–1.00) | 0.000 | 1.00 (1.00, 1.00) | <0.001 |
ALT (U/L) | 1.00 (1.00–1.00) | 0.016 | ||
AST (U/L) | 1.00 (1.00–1.00) | 0.000 | ||
GGT (U/L) | 1.00 (1.00–1.00) | 0.000 | ||
ALP (U/L) | 1.00 (1.00–1.00) | 0.120 | ||
ALB (g/L) | 0.97 (0.95–0.99) | 0.000 | ||
TBIL (μmol/L) | 1.01 (1.00–1.01) | 0.095 | ||
PT (s) | 1.04 (0.98–1.11) | 0.170 | ||
PLT (109/L) | 1.00 (1.00–1.00) | 0.203 | ||
WBC (109/L) | 1.00 (0.98–1.02) | 0.776 | ||
HGB (g/L) | 1.00 (1.00–1.01) | 0.119 | ||
NLR | 1.03 (1.00–1.05) | 0.016 | ||
LMR | 1.01 (1.00–1.02) | 0.037 | 1.01 (1.00, 1.02) | 0.007 |
PLR | 1.00 (1.00–1.00) | 0.003 | ||
MVI‐positive | 2.99 (2.53–3.53) | 0.000 | 2.02 (1.69, 2.42) | <0.001 |
Tumor boundary | 0.81 (0.68–0.95) | 0.012 | ||
Tumor diameter (mm) | 1.01 (1.01–1.01) | 0.000 | 1.01 (1.01, 1.01) | <0.001 |
Tumor number | ||||
1 | Reference | – | – | – |
2 | 1.51 (1.13–2.02) | 0.005 | ||
≥3 | 2.49 (1.87–3.31) | 0.000 | ||
BCLC grade | ||||
0 | Reference | – | – | – |
1 | 2.23 (1.45–3.42) | 0.000 | ||
2 | 6.37 (4.07–9.96) | 0.000 |
Abbreviations: AFP, alpha‐fetoprotein; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; BCLC, Barcelona clinic liver cancer; GGT, gamma‐glutamyl transpeptidase; HBV, hepatitis B; HCC, hepatocellular carcinoma; HGB, hemoglobin; LMR, lymphocyte‐to‐monocyte ratio; MVI, microvascular invasion; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet–lymphocyte ratio; PLT, platelets; PT, prothrombin time; TBIL, total bilirubin; WBC, white blood cells.